← Human Trials & Peer-Reviewed Studies

Cessation of alcohol consumption decreases rate of nicotine metabolism in male alcohol-dependent smokers.

Plain-language guide to PMID 27107849 (2016): randomized controlled trial of Therapeutic nicotine (patch, non-peptide) in 22 men.

Key Facts

PMID
27107849
Journal
Drug and alcohol dependence
Year
2016
Study type
Randomized Controlled Trial
Authors
Gubner NR et al. (9 authors)
DOI
10.1016/j.drugalcdep.2016.04.006

What This Study Did, in Plain Language

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

The current study examined the hypothesis that chronic alcohol abuse can accelerate the rate of nicotine metabolism.

Who Took Part

According to the abstract, 22 men were involved.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

Participants were 22 Caucasian men randomly selected from a sample of 165 smokers entering a 7-week alcohol dependence treatment program in Poland.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nicotine metabolite ratio (NMR, a biomarker for rate of nicotine metabolism) and patterns of nicotine metabolites were assessed at three time points after alcohol cessation.

Data were collected at three time points: baseline (week 1, after acute alcohol detoxification), week 4, and week 7.

What Was Measured

Topics PubMed links to this paper include Alcohol Abstinence, Alcohol Drinking, Alcoholism, Biomarkers, Liver Function Tests, Nicotine and Nicotinic Agonists.

Author keywords: Alcohol abuse, CYP2A6, Cigarettes, Ethanol, Smoking and Tobacco.

What This Means in Plain Language

The paper is a randomized study of Therapeutic nicotine (patch, non-peptide) in 22 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (Drug and alcohol dependence), a journal based in Ireland.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.

Our Notes on the Compound

Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.

Related Pages

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.